The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
A New Substituent Constant, π, Derived from Partition Coefficients
Fujita, T., Iwasa, J., & Hansch, C. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01077a028 · Cited by 1,370
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Ritchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 901
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Smith, D. A., Di, L., & Kerns, E. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3287 · Cited by 898
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Calculating log Poct from structures
Leo, A. J. (1993) · Chemical Reviews · doi:10.1021/cr00020a001 · Cited by 695
Coexistence of passive and carrier-mediated processes in drug transport
Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G. F., Faller, B., Fischer, H., Gerebtzoff, G., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3187 · Cited by 649
Hyafil, F., Pauwels-Vergely, C., Vignaud, P. D., & Grand‐Perret, T. (1993) · PubMed · Cited by 525
Methods and Principles in Medicinal Chemistry
(2008) · Methods and principles in medicinal chemistry · doi:10.1002/series6138 · Cited by 514
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Ritchie, T. J., Macdonald, S. J. F., Young, R. J., & Pickett, S. D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.014 · Cited by 442
Self-citationValkó, K., Bevan, C., & Reynolds, D. (1997) · Analytical Chemistry · doi:10.1021/ac961242d · Cited by 437
Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups
Jamieson, C., Moir, E. M., Rankovic, Z., & Wishart, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060379l · Cited by 423
Using the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
Riley, R. J., McGinnity, D. F., & Austin, R. P. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004259 · Cited by 371
Valkó, K. (2004) · Journal of Chromatography A · doi:10.1016/j.chroma.2003.10.084 · Cited by 365
Molecular obesity, potency and other addictions in drug discovery
Hann, M. M. (2011) · MedChemComm · doi:10.1039/c1md00017a · Cited by 363
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
The importance of plasma protein binding in drug discovery
Trainor, G. L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.51 · Cited by 348
Valko, K., Nunhuck, S., Bevan, C., Abraham, M. H., & Reynolds, D. P. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10494 · Cited by 340
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity
Hill, A. P., & Young, R. J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.016 · Cited by 258
Self-citationCell cultures as models for drug absorption across the intestinal mucosa.
Artursson, P. (1991) · PubMed · Cited by 230
Compound lipophilicity for substrate binding to human P450s in drug metabolism
Lewis, D. F. V., Jacobs, M. N., & Dickins, M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03115-0 · Cited by 172
A quantitative assessment of hERG liability as a function of lipophilicity
Waring, M. J., & Johnstone, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.061 · Cited by 159
Peters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 156
Introduction to computational oral absorption simulation
Sugano, K. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902835506 · Cited by 136
CRAMER, R. D. I. (1980) · Journal of the American Chemical Society · doi:10.1021/ja00526a013 · Cited by 118
CRAMER, R. D. I. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00398a607 · Cited by 100
Wan, H., & Holmen, A. (2009) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620709787581701 · Cited by 99
Physicochemical profiling: overview of the screens
Kerns, E. H., & Di, L. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.08.011 · Cited by 99
Lewis, D. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02412-1 · Cited by 93
The discovery of GSK221149A: A potent and selective oxytocin antagonist
Liddle, J., Allen, M. J., Borthwick, A. D., Brooks, D. P., Davies, D. E., Edwards, R. M., Exall, A. M., Hamlett, C. C. F., Irving, W. R., Mason, A. M., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.008 · Cited by 91
Borthwick, A. D., Liddle, J., Davies, D. E., Exall, A. M., Hamlett, C. C. F., Hickey, D. M. B., Mason, A. M., Smith, I. E. D., Nerozzi, F., Peace, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201287w · Cited by 90
Impact of ion class and time on oral drug molecular properties
Leeson, P. D., St-Gallay, S. A., & Wenlock, M. C. (2010) · MedChemComm · doi:10.1039/c0md00157k · Cited by 87
Reducing the Risk of Drug Attrition Associated with Physicochemical Properties
Leeson, P. D., & Empfield, J. R. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45024-1 · Cited by 85
Tran, T. T. T., Gales, T. L., Maleeff, B. E., Aldinger, T., Polli, J. W., Ayrton, A. D., Ellens, H. M., Bentz, J., & Mittal, A. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20105 · Cited by 74
Improving Compound Quality through in vitro and in silico Physicochemical Profiling
Waterbeemd, H. V. D. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900056 · Cited by 51
Braggio, S., Montanari, D., Rossi, T., & Ratti, E. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.490553 · Cited by 48
Borthwick, A. D., Davies, D. E., Exall, A. M., Hatley, R. J. D., Hughes, J. A., Irving, W. R., Livermore, D. G., Sollis, S. L., Nerozzi, F., Valko, K. L., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060073e · Cited by 45
Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with biaryl P4 motifs
Young, R. J., Borthwick, A. D., Brown, D., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.023 · Cited by 29
Self-citationLead optimization in the nondrug-like space
Zhao, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.002 · Cited by 27
In Silico hERG Modeling: Challenges and Progress
Diller, D. (2009) · Current Computer - Aided Drug Design · doi:10.2174/157340909788451928 · Cited by 24
Tute, M. S. (1996) · Methods and principles in medicinal chemistry · doi:10.1002/9783527614998.ch2 · Cited by 17
Properties Guiding Drug‐ and Lead‐Likeness
Mureşan, S., & Sadowski, J. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621286.ch17 · Cited by 11
Cited by
Rings in Drugs: Miniperspective
Taylor, R. D., MacCoss, M., & Lawson, A. D. G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017625 · Cited by 2,543
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
The influence of lipophilicity in drug discovery and design
Arnott, J. A., & Planey, S. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714363 · Cited by 868
Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation
Lewis, H. D., Liddle, J., Coote, J. E., Atkinson, S. J., Barker, M. D., Bax, B. D., Bicker, K. L., Bingham, R. P., Campbell, M., Chen, Y. H., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1735 · Cited by 779
Metadata
- Authors
- Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 16
- Issue
- 17-18
- Pages
- 822-830
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W1979189217
- Cited by
- 311
- References
- 50
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.